A Case of Exacerbation of Subclinical Hyperthyroidism after First Administration of BNT162b2 mRNA COVID-19 Vaccine

Kana Yamamoto; Takahisa Mashiba; Keisuke Takano; Toshihiko Suzuki; Masahiro Kami; Morihito Takita; Eiji Kusumi; Yasuhiro Mizuno; Tamae Hamaki

doi:10.3390/vaccines9101108

Vaccines (Sep 2021)

A Case of Exacerbation of Subclinical Hyperthyroidism after First Administration of BNT162b2 mRNA COVID-19 Vaccine

Kana Yamamoto,
Takahisa Mashiba,
Keisuke Takano,
Toshihiko Suzuki,
Masahiro Kami,
Morihito Takita,
Eiji Kusumi,
Yasuhiro Mizuno,
Tamae Hamaki

Affiliations

Kana Yamamoto: Department of Reproductive, Developmental and Aging Sciences, Graduate School of Medicine, University of Tokyo, 4-6-1 Shirokanedai, Minato, Tokyo 108-0071, Japan
Takahisa Mashiba: Department of General Internal Medicine, Tokyo Bay Urayasu Ichikawa Medical Center, 3-4-32 Todaijima, Urayasu, Chiba 279-0001, Japan
Keisuke Takano: Department of Endocrinology, Tokyo Bay Urayasu Ichikawa Medical Center, 3-4-32 Todaijima, Urayasu, Chiba 279-0001, Japan
Toshihiko Suzuki: Department of Endocrinology, Tokyo Bay Urayasu Ichikawa Medical Center, 3-4-32 Todaijima, Urayasu, Chiba 279-0001, Japan
Masahiro Kami: Department of Internal Medicine, Navitas Clinic Shinjuku, 4-1-6 Shinjuku 7th Floor of Newoman Bldg, Shinjuku, Tokyo 160-0022, Japan
Morihito Takita: Department of Internal Medicine, Navitas Clinic Tachikawa, 3-1-1 Shibasakicho 4th Floor of Ecute Tachikawa, Tachikawa, Tokyo 190-0023, Japan
Eiji Kusumi: Department of Internal Medicine, Navitas Clinic Tachikawa, 3-1-1 Shibasakicho 4th Floor of Ecute Tachikawa, Tachikawa, Tokyo 190-0023, Japan
Yasuhiro Mizuno: Department of Gastroenterology, Marru-Clinic Yokosuka, 1-8-7 Yonegahamadori, Yokosuka 238-0011, Kanagawa, Japan
Tamae Hamaki: Department of Internal Medicine, Navitas Clinic Shinjuku, 4-1-6 Shinjuku 7th Floor of Newoman Bldg, Shinjuku, Tokyo 160-0022, Japan

DOI: https://doi.org/10.3390/vaccines9101108
Journal volume & issue: Vol. 9, no. 10
p. 1108

Abstract

Read online

COVID-19 vaccines are the most critical measure for controlling the COVID-19 pandemic; however, we have little information on their complications. We experienced a case of a patient who developed hyperthyroidism complicated with atrial fibrillation and heart failure on the sixth day after the first dose of COVID-19 vaccination. This case report shows the importance of considering hyperthyroidism as a possible complication after COVID-19 vaccination.

Published in Vaccines

ISSN: 2076-393X (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine
Website: http://www.mdpi.com/journal/vaccines

About the journal

Abstract

Keywords